Author:
Saad Fred,de Bono Johann,Barthélémy Philippe,Dorff Tanya,Mehra Niven,Scagliotti Giorgio,Stirling Adam,Machiels Jean-Pascal,Renard Vincent,Maruzzo Marco,Higano Celestia S.,Gurney Howard,Healy Cynthia,Bhattacharyya Helen,Arondekar Bhakti,Niyazov Alexander,Fizazi Karim
Reference22 articles.
1. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician’s choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation;Rugo,2018
2. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial;de Bono;Lancet Oncol,2021
3. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers;de Bono;Cancer Discov,2017
4. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial;Hurvitz;Oncologist,2020
5. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO);Turner;Clin Cancer Res,2019
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献